Citizens Reiterates Market Outperform on Nuvation Bio, Maintains $10 Price Target

Benzinga Newsdesk www.benzinga.com Negative 82.8%

Neg 82.8% Neu 0% Pos 0%

Citizens analyst Silvan Turkcan reiterates Nuvation Bio (NYSE:NUVB) with a Market Outperform and maintains $10 price target.